Recent IPO activity in October 2026, including priced offerings from Retension Pharmaceuticals, TRex Bio, Iambic Therapeutics, and City Therapeutics alongside multiple SPAC launches, underscores an active pipeline supported by biotech sector momentum and equity market access. For larger private firms, trader-implied odds hinge on valuation gaps, revenue trajectories, and macroeconomic factors such as Treasury yields and risk appetite. With the December 31, 2026 resolution approaching, key catalysts include potential filings or pricing windows for names like Anthropic or SpaceX, tempered by historical delays from market volatility and regulatory scrutiny. Aggregated capital at risk on Polymarket reflects this balance between ongoing smaller deals and uncertainty around flagship timelines.